Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 22,394

Document Document Title
WO/2018/165913A1
Provided are a specific chimeric antigen receptor targeting NKG2DL and a CAR-T cell thereof, as well as a preparation method and the use thereof. The CAR-T cell can effectively target and attack a plurality of tumour cells, and can be us...  
WO/2018/166468A1
Disclosed are an IgG-like long-acting immune fusion protein and the use thereof. The IgG-like long-acting immune fusion protein consists of an effector molecule and a constant region of an IgG antibody, and the effector molecule is linke...  
WO/2018/170458A1
Described herein are chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.  
WO/2018/170152A1
The disclosure provides, in part, compositions comprising mature recombinant mature Complement Factor I (CFI) protein and methods of making and using those compositions.  
WO/2018/166507A1
Provided are a recombinant bifunctional fusion protein, a preparation method therefor and use thereof. In particular, the provided bifunctional fusion protein is formed by series binding of an anti-human CD20 monoclonal antibody and a fi...  
WO/2018/166119A1
Disclosed are a polypeptide targeted at promoting EGFR protein degradation, or a derivative of the polypeptide and the use thereof in the preparation of a drug for treating tumours. The amino acid sequence of the polypeptide is as shown ...  
WO/2018/165752A1
The present description relates to a conjugated anti-interleukin-5 receptor α-subunit (IL-5Rα) compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear loca...  
WO/2018/170096A1
The present disclosure is directed to bispecific antibodies binding to CD4 and CD8. In a further embodiment, there is provided a method of treating diabetes in a subject comprising providing the bispecific antibodies binding to CD4 and C...  
WO/2018/166461A1
Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can i...  
WO/2018/165328A1
Disclosed herein are compositions, methods, and systems for the purification and/or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substan...  
WO/2018/165629A1
Some aspects of this disclosure provide compositions, strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g...  
WO/2018/165208A1
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.  
WO/2018/163947A1
Disclosed are: a fusion protein containing an R1-EN and a protein fused to a C-terminus or an N-terminus of said R1-EN or a protein having said R1-EN in a loop; a protein crystal production method including a step for crystallizing said ...  
WO/2018/158727A1
The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-β) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or acti...  
WO/2018/160908A1
The present disclosure provides technologies for modulating gene expression.  
WO/2018/160877A1
Provided are methods and compositions directed towards the treatment of an individual having cancer by providing adoptive cell transfer therapy and administering to the individual a long acting IL-2Rαβ-biased agonist.  
WO/2018/156802A1
Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.  
WO/2018/156735A1
Disclosed are compositions and methods for gene transfer in immune effector cells, e.g. to create chimeric antigen receptors (CARs). In particular, polypeptides are disclosed that comprising an antigen-binding region and a heparin bindin...  
WO/2018/157164A1
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an...  
WO/2018/157163A1
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for ...  
WO/2018/149315A1
Provided are a carrier for displaying a target polypeptide and a use thereof. Particularly, core antigens of three types of hepatitis B virus from bats are modified to be used as a protein carrier for displaying a human T cell epitope. A...  
WO/2018/149358A1
Provided is an antibody for specifically identifying IL-13RA2, which can be used for preparing a targeted antitumor medication and a medication for diagnosing a tumor.  
WO/2018/148847A1
The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the...  
WO/2018/148507A1
The present application provides nerve growth factor (NGF) variants with improved in vivo stability, methods for producing and purifying NGF variants, as well as potential therapeutic applications.  
WO/2018/148445A1
Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.  
WO/2018/147960A1
Provided herein are diabodies that comprise extension sequences and antigen binding constructs that comprise extension sequences.  
WO/2018/145182A1
The present invention relates to novel hybrid peptides, developed by combining peptide fragments from membrane surface proteins present in microorganisms that cause anaplasmosis, and in particular, bacteria of the species Anaplasma margi...  
WO/2018/148649A1
Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian- inhibiting substance protein are provided. These protein...  
WO/2018/148541A1
Polypeptides are provided that include an actinohivin variant polypeptide. The actinohivin variant polypeptide can be operably connected to an antibody fragment, such as a fragment crystallizable (Fc) region of immunoglobulin (Ig) G. Nuc...  
WO/2018/145648A1
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID ...  
WO/2018/146074A1
The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moiet...  
WO/2018/145649A1
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID ...  
WO/2018/142409A1
This invention provides a chemically modified, peptoid bound reverse osmosis (RO) membrane exhibiting an improved flux efficiency along each of the units in a multiple-unit RO pressure vessel.  
WO/2018/145068A1
Provided herein are engineered systems and methods for establishing DNA adenine methylation at specific genomic locations and using DNA adenine methylation as an artificial chemical "handle" on the genome. These systems and methods allow...  
WO/2018/144968A1
In certain aspects, the present disclosure relates to methods of treating, preventing, and reducing the severity or progression of heart failure or one or more complications of heart failure. For example, the disclosure provides various ...  
WO/2018/140519A1
Provided herein are agents, compositions, and methods for agricultural pest control, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host insect (e.g., agricultural pest), the alteration ...  
WO/2018/140456A1
Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need the...  
WO/2018/140611A1
Provided herein are methods and compositions for the treatment of diseases associated with angiogenesis and neovascularization. In one aspect, the invention relates to a method for treating a condition in an eye of a patient in need ther...  
WO/2018/137705A1
Disclosed herein are antigen binding units that specifically bind to CD47. Further disclosed herein are polynucleic acids encoding said antigen binding units, vectors comprising said polynucleic acids, and hybridomas and host cells compr...  
WO/2018/137173A1
Disclosed are a method for improving the sensitivity of a plant to a gibberellin inhibitor and the use thereof. The method provided in the present invention for improving the sensitivity of a plant to a gibberellin inhibitor comprises th...  
WO/2018/138709A1
A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amy...  
WO/2018/140507A1
Provided herein are methods and compositions useful for human health, e.g., for targeting one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the modulation resulting in a decrease...  
WO/2018/140518A1
Provided herein are agents, compositions, and methods useful for animal health, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen ...  
WO/2018/140831A3
Various compositions are disclosed. The compositions of conjugates comprising immune-stimulatory compounds are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treat...  
WO/2018/135598A1
[Problem] To provide a novel method for fluorescent labeling of intracellular proteins using fluorescence ON/OFF control technology. [Solution] A method for fluorescent labeling of intracellular proteins, wherein the method for fluoresce...  
WO/2018/133222A1
The present invention discloses a method for visually marking a genomic site and an application thereof in the detection of cell and organism aging levels. The present invention integrates thioredoxin (TRX) at the C-terminus of a transcr...  
WO/2018/136725A1
Provided herein are conditionally activated antigen-binding proteins comprising a protease-activated domain binding to an innate immune cell, at least one half-life extension domain, and two or more domains binding to one or more target ...  
WO/2018/133877A1
Provided in the present invention are a specific antibody of BCMA and a BCMA-targeting immune effector cell, and also provided are a chimeric antigen receptor-modified T cell prepared using the antibody and the use thereof.  
WO/2018/129624A1
The present invention provides a vaccine comprising a peptide antigen, one terminal end being coupled to a carrier molecule, and the other terminal end of the peptide being linked to a non-immunogenic moiety such as a saccharide. The thu...  
WO/2018/130000A1
Disclosed in the present invention are a self-assembled serially-connected cell-penetrating peptide nano-particulate antibacterial agent capable of penetrating the blood brain barrier, a preparation method therefor, and uses thereof. The...  

Matches 1 - 50 out of 22,394